DrMugeloveskidneys

MD.FISN, Professor of Nephrology at Dokuz Eylul University, fanatical about Ataturk, Vanderbilt👍,from Ankara, lives in İzmir 1881❤️ 1903🦅1952🙏

[NDT @NDTsocial]

Prevalence of anti-rituximab antibodies in autoimmune forms of glomerulonephritis and podocytopathies

🔓https://t.co/JEgXk26bdK

[Hypertension @HyperAHA]

REVIEW: Fibromuscular Dysplasia: Emerging Concepts Beyond the International Consensus

https://t.co/brjVoSRxmp

[Ahmed Bennis MD 🫀 @drbennisahmed]

Best overall discontinuation profile: ARB+CCB, ARB+β-blocker, ARB alone

Edema: ARB+thiazide best; CCB-containing regimens rank worst (expected)

Cough: ARB combos best; ACEI combos worst (ACE-related)

Dizziness: Placebo & CCB+thiazide top; ARB+CCB+thiazide worst

[NDT @NDTsocial]

Pathophysiology of pregnancy-associated acute kidney injury

https://t.co/YxuZpHhbJ4

[Hypertension @HyperAHA]

RESEARCH ARTICLE: Blood Pressure Change and Subclinical Target Organ Damage in Mid-Adulthood

https://t.co/K8YRtK6Z60

[AJKD @AJKDonline]

Obesity in CKD: Core Curriculum 2026

https://t.co/zH9CjtaBwS (FREE)

@kramer_holly

[AJKD @AJKDonline]

Obesity Management in End-Stage Kidney Disease: Pathways to Improve Kidney Transplant Access

https://t.co/Z0gsB5rBT7 (FREE)

@poojabudh

[KDIGO @goKDIGO]

Read the new KDIGO Direct for the latest news from KDIGO: https://t.co/SR7cXH8V13

In this issue:
- KDIGO publishes new reports on B Cell-Mediated Therapies and Green Dialysis Conference Carbon Footprint and Sustainability

- KDIGO launches new FSGS podcast series

- KDIGO at #ERA26

- New KDOQI US commentaries on KDIGO Guidelines

- New CME/CE activities

- Additional resources

[JAMA @JAMA_current]

💡 JAMA Insights: #GLP1 receptor agonists and dual incretin agents support weight loss with minimal lifestyle counseling, but diet and activity advice remain necessary for safety and long-term success in #Obesity care.

https://t.co/pByOSM0aZR

[CKJ @CKJsocial]

Disparity in the regulation and prevention of water versus sodium imbalance in heat-stress nephropathy: a phylogenetic perspective

https://t.co/havCsE6Zsb

[Edgar V. Lerma 🇵🇭 @edgarvlermamd]

Fabry Disease: Current Perspectives on Diagnosis and Management Strategies ca. 2026 from @akdhjournal @SaynaNorouzi @DrAnjayRastogi @ZohrehGh7
#Nephpearls

👉🏼 https://t.co/LPWy18PdR2

[CKJ @CKJsocial]

Measuring effectiveness in immunoglobulin A nephropathy: what are we looking for?

https://t.co/unsUso2tn3

[Abdelhamed Hamdy @Abdelhamed6261]

CKM

[Brendon Neuen @brendonneuen]

PPT slides for the FIND-CKD primary presentation are now freely available - including the glomerular disease data & INFINITY (IPD meta-analysis).

Use them, adapt them, share them as you like

All FIND-CKD presentations & publications now live at https://t.co/Nh6uJ3kPZA

#ERA26

[Hans-Joachim Anders @hjanders_hans]

Now online in @NDTsocial by @P_Rossing

GLP-1ra in T2DM: CV protection versus ocular safety

🧐Rapid and substantial reductions of hyperglycemia may cause worsening of unstable diabetic retinopathy!

▶️https://t.co/gewsUExCzp

[CKJ @CKJsocial]

Pre-transplant and persistent post-transplant hyperparathyroidism and kidney transplant outcomes: a systematic review and meta-analysis

https://t.co/HeDBvj4gKw

[Shreshta Tripathi @ShreshtaT]

CKM Syndrome: Think beyond eGFR.

Stage 0️⃣: No CKM risk factors → Prevention only 🏃🥗

Stage 1️⃣: Excess/dysfunctional adiposity ⚖️
→ Obesity, central adiposity, prediabetes

Check 👉https://t.co/JLS7QHXVQt

[Ahmed Bennis MD 🫀 @drbennisahmed]

Key factors for digital health researchers:
✅ Clear communication with participants
✅ Reliable access to required technology
✅ User-friendly design
✅ Simple, effective recruitment & screening
✅ Strong privacy & security protections
✅ Robust infrastructure

[Hypertension @HyperAHA]

RESEARCH ARTICLE: Effects of Antihypertensive Therapy on Pre- and Postnatal Maternal Hemodynamics @JuliaBinder9 @erkan_uog @profAsmaKhalil

https://t.co/pMcxe8qenu

[Ahmed Bennis MD 🫀 @drbennisahmed]

Efficacy and safety of finerenone in patients with chronic kidney disease: an individual participant data pooled analysis (INFINITY)

finerenone reduced the risk of CKD progression, including kidney failure alone, and reduced HF hospitalisation, CV death, and all-cause death.